Treatment with trospium XR compared with placebo resulted in significantly greater decreases from baseline in the mean number of daily toilet voids ( -2.5 vs -1.5 ; P < .05 ) and urgency urinary incontinence episodes ( -2.3 vs -1.4 ; P < .05 ) in men at week 12 ( the coprimary efficacy variables ) .
